Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde

US7989501B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Susan D. Mertins · Frederick, US
• Susan E. Bates · Bethesda, US
• David G. Covell · Bethesda, US
• Geoffrey W. Patton · Wheaton, US
• Melinda G. Hollingshead · Birmingham, US
• Rao Vishnuvajjalla · Rockville, US

Key dates

• Filing date: Oct 14, 2005
• Grant date: Aug 2, 2011
• Expiry date: May 16, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention features methods of treating a mammalian subject having renal cancer by administration of certain dimethylsulfonate compounds, such as a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde. The present invention further features administration protocols and dosing schedules for methods of treating patients having renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein.